Creon market seen growing on pancreatic disease burden and personalized care

The Creon market is projected to expand as pancreatic disorders rise, healthcare spending increases and personalized medicine gains ground. A new Business Research Company report says North America led in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Creon is used to treat digestive enzyme deficiencies tied to conditions like cystic fibrosis, chronic pancreatitis and pancreatic surgery. - Growth in pancreatic disease, longer-term digestive care and broader access to treatment can lift demand for pancrelipase therapies. - The market also reflects a wider shift toward personalized medicine and nutritional management in chronic care.

What happened: - The Business Research Company released a global Creon market report on Nov. 2, 2026. - The report analyzes market growth, segmentation, key competitors, regional trends and forecast drivers. - A free sample is available here, and the full report is available here.

The details: - Creon contains pancrelipase, a mix of lipase, protease and amylase. - The medicine is taken orally with meals and snacks. - Creon helps patients absorb fats, proteins and carbohydrates when the pancreas does not make enough enzymes. - Historical market growth was supported by proven pancrelipase efficacy, more cystic fibrosis patients, higher pancreatic surgery volumes, improved diagnosis of exocrine pancreatic insufficiency and gastroenterologist prescribing. - The report says future growth should be supported by more chronic digestive disease, an aging population, stronger focus on nutritional management, more outpatient digestive care and greater awareness of enzyme deficiencies. - Reported trends include wider adoption of pancrelipase therapies, more use of pancreatic enzyme replacement, long-term management of digestive disorders, better adherence from optimized dosing and more post-surgical use. - Rising pancreatic disorders are a key growth driver because these conditions impair enzyme production and can disrupt digestion and blood sugar regulation. - The report points to chronic alcohol use, smoking, obesity, diabetes, genetic predisposition and better diagnostics as contributors to the rise in pancreatic disorders. - Cancer Research UK projected in February 2023 that new pancreatic cancer cases in the UK will increase from about 12,500 a year in 2023-2025 to nearly 16,000 by 2038-2040. - The report estimates that rise at about 5%, or 19 cases per 100,000 people by the end of the forecast period. - Personalized medicine is another growth factor because it can tailor pancreatic enzyme replacement to individual patient needs. - The Personalized Medicine Coalition said in February 2024 that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - Higher healthcare spending also supports access to medications like Creon. - The UK Office for National Statistics said in May 2024 that healthcare spending grew 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. - North America held the largest Creon market share in 2025. - Asia-Pacific is projected to post the fastest growth during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - New 2026 report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis, future trend analysis and updated graphics and tables.

Between the lines: - The report frames Creon as a niche but durable pharmaceutical market tied to demographic aging, chronic disease prevalence and better diagnosis. - The fastest-growing opportunities appear to be outside North America, with Asia-Pacific positioned for the strongest expansion. - The focus on personalized medicine suggests future competition may center on dosing precision, adherence and care-setting expansion rather than only drug formulation.

What's next: - The report expects continued growth as digestive disease rates climb and enzyme-deficiency awareness expands. - Outpatient digestive care and post-surgical use may become more important commercial channels. - Regional shifts will matter, especially if Asia-Pacific demand accelerates as projected. - Interested readers can contact the company through the report page and sample request links above.